Nucleic Acid Therapeutics: From Base Pairs to Bedsides
Organizer(s): Alan M. Gewirtz (in memoriam), Anastasia Khvorova and Mark A. KayDate: January 10 - 15, 2012
Location: Eldorado Hotel & Spa, Santa Fe, NM, USA
Small molecules and antibodies have revolutionized the treatment of cancer and appear promising for the treatment of many other diseases as well. Nonetheless, there are many candidate therapeutic targets that are not amenable to attack by the current generation of targeted therapies and, in a small but growing number of patients, resistance to initially successful targeted treatments evolves. This symposium will focus on the medicinal promise of pre- and post- transcriptional gene silencing (PPTGS) using oligodeoxynucleotides, small interfering RNA, microRNA and other nucleic acid based molecules. The meeting is motivated by the hypothesis that these molecules can be developed into effective drugs for the treatment of many common diseases that are collectively responsible for a great deal of human suffering. As this symposium will highlight, there is still much to do, but many in the field now hope that the time has finally arrived when “antisense” therapies will finally come of age and fulfill their promise as the magic bullets of the 21st century.
Scholarship Deadline: September 15 2011
Discounted Abstract Deadline: September 15 2011
Abstract Deadline: October 13 2011
Discounted Registration Deadline: November 10 2011
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Isis Pharmaceuticals, Inc.
Regulus Therapeutics Inc.
Xavier J. de Mollerat du Jeu